This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dynavax: The BioRunUp Trade Into An FDA Panel

As the Heplisav FDA panel nears, I expect investor anticipation and speculation to increase causing Dynavax's share price to rise -- a nice set up for an 8-10 week BioRunUp swing trade. As always, make sure to close the Dynavax position before FDA releases briefing documents for the Heplisav panel on Nov. 12 -- two business days before the panel.

BioRunUp swing trading is also an effective biotech investing strategy for clinical trial data announcements. Nailing down the timing on a clinical trial swing trade is more difficult because companies rarely pre-announce a specific date for the release of data from studies. However, companies do often provide rough guidance i.e. late September or the fourth quarter.

Like with swing trades involving PDUFA dates, the knowledge that clinical trial results are pending tends to push biotech stock prices higher. The same phenomenon is at work: Investor hope and greed mix to create bullish momentum that accelerates as the expecting release of clinical data nears. BioRunUp traders profit by playing the run up in share price that precedes the release of clinical trial data. But again, remember the cardinal rule: Do not hold the trade into the event. If the swing trade works, a BioRunUp trader books a nice profit without having to risk worrying about whether a clinical trial produces positive results or not.

I've been able to turn a few thousand dollars into a few hundred thousand dollars in my personal trading account using the BioRunUp swing trading strategy. Subscribers to the trading community web site that I helped found have, collectively, booked millions of dollars in verified profits.

In future columns for TheStreet, I will be discussing the BioRunUp strategy in more detail with actionable trading ideas.

Messier is currently long Dynavax shares.

Follow Mark Messier on Twitter.

Mark Messier is the founder of Messier is a DOJ-certified Criminal Intelligence Analyst and former IT professional, specializing in law enforcement applications. In April 2010, Messier founded the subscription-based stock-trading web site to share his biotech trading ideas with the online investor community. Messier enjoys spending time with his wife and two young boys and visiting his "home away from home" in Costa Rica.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DVAX $21.99 -5.66%
AAPL $132.65 1.82%
FB $81.91 0.47%
GOOG $555.37 -1.71%
TSLA $231.55 6.01%


DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs